AFT Pharmaceuticals Limited (NZE:AFT)

Market Cap	352.35M +31.8%
Revenue (ttm)	236.25M +19.0%
Net Income	17.45M +50.3%
EPS	0.16 +59.1%
Shares Out	104.87M
PE Ratio	20.77
Forward PE	22.48
Dividend	0.02 (0.54%)
Ex-Dividend Date	Jun 18, 2025

Volume	16,261
Average Volume	7,634
Open	3.360
Previous Close	3.360
Day's Range	3.350 - 3.400
52-Week Range	2.410 - 3.800
Beta	0.38
RSI	33.66
Earnings Date	May 22, 2026

About AFT Pharmaceuticals

AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, pain management, skin care, vitamins, supplements, gastrointestinal, dermatology, and hospital. It has a research and development collaboration with Belgium’s Hyloris Pharmaceuticals to develop a novel innovative injecta...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 119
• Stock Exchange: New Zealand Stock Exchange
• Ticker Symbol: AFT

Financial Performance

In fiscal year 2025, AFT Pharmaceuticals's revenue was 208.02 million, an increase of 6.45% compared to the previous year's 195.41 million. Earnings were 11.96 million, a decrease of -23.36%.